Rea­ta’s ‘reg­u­la­to­ry con­cerns’ turn in­to three-month de­lay on FDA de­ci­sion for Friedre­ich’s atax­ia drug

In its Q2 re­port Mon­day, Rea­ta Phar­ma­ceu­ti­cals said that the FDA con­tin­ues to have con­cerns about its Friedre­ich’s atax­ia drug.

On Tues­day, those con­cerns man­i­fest­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER